BG Medicine, Inc. (NASDAQ:BGMD) tumbled badly by close at 18% on Thursday and joined in the list of top laggards of the day. The reason behind the fall was the company’s pricing of its public offering of the common stock. BG Medicine, Inc. (NASDAQ:BGMD) shares after opening at $ 1.56 moved to $1.58 on last trade day and at the end of the day closed at $1.46. Company price to sales ratio in past twelve months was calculated as 12.54 and price to cash ratio as 4.44. BG Medicine, Inc. (NASDAQ:BGMD) showed a negative weekly performance of -23.96%.
Novadaq Technologies Inc(NASDAQ:NVDQ) shares saw strong trading volume on Monday after Canaccord Genuity raised their price target on the stock from $23.00 to $26.00, Analyst Ratings Network.com reports. Canaccord Genuity currently has a buy rating on the stock. 732,739 shares traded hands during trading, an increase of 67% from the previous session’s volume of 438,818 shares.The stock last traded at $18.55 and had previously closed at $20.81. Novadaq Technologies Inc. (NASDAQ:NVDQ) shares fell -7.26% in last trading session and ended the day on $19.30. Novadaq Technologies Inc. (NASDAQ:NVDQ) yearly performance is 86.47%.
Puma Biotechnology, Inc. (NYSE: PBYI), a development stage biopharmaceutical company, announced the presentation of positive results from the Phase II clinical trial of Puma’s investigational drug PB272 (neratinib) for the neoadjuvant treatment of breast cancer (I-SPY 2 TRIAL) in an oral presentation at the American Association for Cancer Research (AACR) Annual Meeting 2014 in San Diego, California. The presentation entitled “Neratinib plus Standard Neoadjuvant Therapy for High-Risk Breast Cancer: Efficacy Results from the I-SPY 2 TRIAL” was presented at the session entitled “Clinical Trials Symposium: Biomarker Driven Clinical Trials.” Puma Biotechnology Inc (NYSE:PBYI) shares moved down -18.30% in last trading session and was closed at $86.94, while trading in range of $ 78.96 – 118.22. Puma Biotechnology Inc (NYSE:PBYI) year to date (YTD) performance is -16.02%.
Unilife Corp.UNIS -7.20%, a supplier of injectable drug delivery systems based in York, Pa., named Controller Dennis Pyers its interim CFO. Mr. Pyers succeeds Richard Wieland, who is leaving after four years as CFO. Unilife didn’t immediately disclose any new compensation for Mr. Pyers. Mr. Wieland said in a press release that the $60 million financing from OrbiMed it announced last week left Unilife “well financed,” and it is an appropriate time for a new CFO during its next phase. Unilife Chief Executive Alan Shortall also said its next CFO will “complement our future needs as a large, rapidly growing” company. Unilife Corp (NASDAQ:UNIS) weekly performance is -14.50%. On last trading day company shares ended up $3.48. Unilife Corp (NASDAQ:UNIS) distance from 50-day simple moving average (SMA50) is -21.51%. Analysts mean target price for the company is $7.70.
Leave a Reply